Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx Raises $20M for Structural Proteomics Efforts

NEW YORK, Oct 3 - Structural genomics company Syrrx said Tuesday it has completed a $20 million Series B round of venture financing.

MPM Asset Management led the private placement. Nicholas Galakatos, general partner at MPM Asset Management, will be joining Syrrx's board of directors.

Syrrx uses proprietary high throughput technology platforms to solve protein structures that can be used along with genomic and computational approaches to design novel pharmaceuticals.

The company’s tools were developed by engineers recruited from the automotive industry and enable an assembly line approach, significantly impacting the cost and speed of drug design, the company said.

" We've applied auto industry principles to the next step in genomic research," Peter Schultz, Syrrx’s director, said in a statement.

Syrrx currently has 18 employees and is located in San Diego.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.